Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riliprubart versus IVIg in chronic inflammatory demyelinating polyneuropathy
jRCT2031240206Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Nov 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Sanofi. Primary endpoints: Percentage of participants experiencing a response and Percentage of participants randomized to riliprubart who responded during part A and had a lasting response during the open-label extension. Started Nov 2024; status: recruiting.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2031240206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240206.